Friday 21 March 2025

Pharma & Biotech Start-up & Scale-up News

Featured

Oxford BioTherapeutics
OBT is a clinical stage oncology company based in Oxford, UK and San Jose, USA.
Pharmaceutical
Lexicon pivots back to pipeline after FDA rejection
25 November 2024
Pharmaceutical
The week in pharma: action, reaction and insight – week to November 1
3 November 2024

Latest Ones To Watch News

Biotechnology
Well-travelled Abizer Gaslightwal gets top job at Akari
20 March 2025
Pharmaceutical
Immuneering appoints Igor Matushansky as CMO
20 March 2025
Pharmaceutical
Neurocrine touts further positive trial results for Ingrezza
20 March 2025
More ones to watch news >
Reset all filters
Refine Search
Pliant Therapeutics
Pliant Therapeutics
Nuvation Bio
Nuvation Bio
Enanta Pharmaceuticals
Basilea
Exsilio Therapeutics
Aphaia Pharma
Avextra
Aurion Biotech
āshibio
UTILITY Therapeutics
Enlaza Therapeutics
Jacobio Pharma
SFA Therapeutics
Reunion Neuroscience
Atopia Therapeutics
Prologue Medicines
Lykos Therapeutics
Attovia Therapeutics
Ajax Therapeutics
Cartesian Therapeutics


Today's issue

Well-travelled Abizer Gaslightwal gets top job at Akari
Biotechnology
Well-travelled Abizer Gaslightwal gets top job at Akari
20 March 2025
Pharmaceutical
Immuneering appoints Igor Matushansky as CMO
20 March 2025
Biotechnology
New low for Elevation after abandoning EO-3021
20 March 2025
Pharmaceutical
Paratek to buy Optinose for up to $330 million
20 March 2025
Pharmaceutical
Neurocrine touts further positive trial results for Ingrezza
20 March 2025
Biotechnology
Chugai launches Lunsumio in Japan for follicular lymphoma
20 March 2025
Pharmaceutical
UK pharma leaders warn industry levy is driving investment away
20 March 2025

Company Spotlight

OBT is a clinical stage oncology company based in Oxford, UK and San Jose, USA.




Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze